SLS · SELLAS Life Sciences Group, Inc.
$12.48
-0.71 (-5.38%)
At close · Jul 20
Going-concern doubt
— cleared May 12, 2026
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements - Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company expects its cash and cash equivalents, together with the $7.5 million in proceeds from warrant exercises subsequent to March 31, 2026, will be sufficient to fund its current planned operations for at least the next twelve months from the date of issuance of these consolidated financial statements, although the Company may pursue additional capital resources through public or private equity or debt financings or by entering into additional license agreements or collaborations with other companies.”View the 10-Q filed May 12, 2026
Market Cap
$2.32B
Shares
186.03M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2023
Net Income
-$26.86M
+13%
FY2025
Gross Margin
85.58%
+58.4pp
FY2015
Operating Margin
-4195%
-3862.2pp
FY2022
Diluted EPS
-$0.25
+50%
FY2025
Operating Cash Flow
-$28.39M
+19.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | $0 | $1M | $7.6M | $1.9M | — | — | — | $1.44M | $1.44M | $9.32M | $2.49M | — | — | |
| $422K | — | — | $525K | $317K | $6000 | $26K | $118K | -$266K | -$462K | — | — | — | — | — | — | |
| $0 | $0 | $0 | $0 | $100K | $200K | — | — | — | — | — | — | $1.4M | $520K | — | — | |
| — | — | — | — | — | — | — | — | — | — | $1.23M | $1.23M | $2.54M | $967K | — | — | |
| — | — | — | — | — | — | — | — | — | — | 85.58% | 85.58% | 27.21% | 38.88% | — | — | |
| $17.95M | $16.02M | $19.1M | $24.01M | $20.27M | $15.67M | $9.28M | $7.29M | $8.77M | $6.07M | $19.86M | $23.61M | $27.67M | $21.08M | $25.79M | $50.65M | |
| $4.12M | — | — | — | — | — | — | — | $900K | — | — | — | — | — | $46.29M | $40.32M | |
| — | $12.25M | $12.42M | $13.86M | $12.58M | $11.32M | $9.6M | $9.92M | $12.77M | $15.09M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $0 | — | — | — | $440K | $131K | — | — | |
| — | — | — | — | — | — | — | — | — | $3000 | $142K | $355K | $362K | $452K | $713K | $664K | |
| — | — | — | — | — | — | — | — | — | — | $31.87M | $34.22M | $43.9M | $36.33M | $72.08M | $90.96M | |
| $31.46M | $28.27M | $31.51M | $37.87M | $42.95M | $32.89M | $18.88M | $20.04M | $31.09M | — | — | — | — | — | — | — | |
| -$31.46M | -$28.27M | -$31.51M | -$37.87M | -$41.95M | -$25.29M | -$16.98M | — | — | -$23.04M | -$31.87M | -$34.22M | -$43.9M | -$33.84M | — | — | |
| — | — | — | — | -4195% | -332.82% | -893.79% | — | — | — | -2219.15% | -2383.01% | -471.08% | -1360.68% | — | — | |
| — | — | — | — | — | — | — | — | — | -$23.04M | -$31.73M | -$33.87M | -$43.54M | -$33.39M | — | — | |
| $2.01M | $1.41M | $632K | $529K | $649K | $4.36M | — | -$19.37M | -$29.05M | — | $21.01M | -$4.37M | $15.62M | -$41.79M | -$497K | $13.7M | |
| — | -$26.86M | -$30.88M | -$37.34M | -$41.3M | -$20.94M | -$16.77M | -$19.37M | -$29.05M | -$23.5M | -$10.86M | -$38.59M | -$28.28M | -$75.63M | -$72.58M | -$77.27M | |
| — | $0 | $0 | $0 | $0 | -$237K | -$17K | -$81K | -$1.38M | $253K | $243K | $365K | $0 | $1.05M | -$1.05M | — | |
| -$29.46M | -$26.86M | -$30.88M | -$37.34M | -$41.3M | -$20.7M | -$16.76M | -$19.29M | -$27.67M | -$23.75M | -$23.55M | -$63.9M | -$36.61M | -$76.68M | -$112.24M | -$77.27M | |
| — | — | — | — | -4130.1% | -272.36% | -881.95% | — | — | — | -1639.9% | -4450% | -392.81% | -3083.15% | — | — | |
| — | — | — | — | — | -$20.7M | -$16.84M | -$27.95M | -$41.25M | -$24.43M | — | — | — | — | — | — | |
| USD/shares | — | -$0.25 | -$0.50 | -$1.34 | -$2.13 | -$1.34 | — | — | — | — | -$0.51 | -$0.12 | -$0.06 | -$0.46 | — | — |
| USD/shares | — | -$0.25 | -$0.50 | -$1.34 | -$2.13 | -$1.34 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 109.05M | 61.2M | 27.78M | 19.4M | 15.48M | 7.98M | 2.56M | 13.08M | 2.34M | 9.96M | 155.26M | 119.39M | 90.18M | 62.48M | — |
| shares | — | 109.05M | 61.2M | 27.78M | 19.4M | 15.48M | 7.98M | 2.56M | 13.08M | 2.34M | 9.96M | 155.26M | 119.39M | 90.18M | 62.48M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2019: $7.34M in buybacks, $487K in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.46×
EV/EBIT
—
Biotechnology median 26.04×
P/E (TTM)
—
Biotechnology median 7.03×
Key facts
CIK
1390478
CUSIP
81642T209
13F (30d)
19 filings
19 filers
Visit website
Investor relations